Goldman Sachs
CTNM

Goldman Sachs’s Contineum Therapeutics CTNM Stock Holding History

Goldman Sachs’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.15M Buy
497,255
+190,147
+62% +$2.49M ﹤0.01% 3435
2026
Q1 		$4.01M Buy
307,108
+201,514
+191% +$2.7M ﹤0.01% 3926
2025
Q4 		$1.21M Buy
105,594
+75,459
+250% +$861K ﹤0.01% 4986
2025
Q3 		$354K Sell
30,135
-30,787
-51% -$248K ﹤0.01% 5684
2025
Q2 		$242K Buy
60,922
+46,701
+328% +$203K ﹤0.01% 5565
2025
Q1 		$99.3K Sell
14,221
-12,144
-46% -$110K ﹤0.01% 5785
2024
Q4 		$386K Buy
+26,365
New +$418K ﹤0.01% 5381

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs's CTNM Position: Q2 2026 in Review

Goldman Sachs increased its Contineum Therapeutics (CTNM) stake by 62% in Q2 2026, buying an estimated $2.49M and bringing the position to 497,255 shares worth $8.15M. The position accounts for ﹤0.01% of the portfolio, ranked #3435.

Goldman Sachs first reported a position in CTNM in Q4 2024 and has held it in 7 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Goldman Sachs held 497,255 shares of Contineum Therapeutics worth $8.15M as of Q2 2026.
  • Goldman Sachs bought 190,147 Contineum Therapeutics shares in Q2 2026, an estimated $2.49M.
  • Contineum Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3435 holding.
  • Goldman Sachs first reported a position in Contineum Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.